The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years’ experience of a single center

BACKGROUND: Myelodysplastic syndrome (MDS) is a rare disease in children and the treatment option before the allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rarely reported. Our main objective was to report our single-center experience with the DNA-hypomethylating agent, decitabine...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Junyan, Hu, Yixin, Gao, Li, Xiao, Peifang, Lu, Jun, Hu, Shaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137053/
https://www.ncbi.nlm.nih.gov/pubmed/35624441
http://dx.doi.org/10.1186/s12887-022-03376-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137053/
https://www.ncbi.nlm.nih.gov/pubmed/35624441
http://dx.doi.org/10.1186/s12887-022-03376-1

Ejemplares similares